Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RSV ΔNS2/Δ1313/I1314L and RSV 276 vaccines in RSV-seronegative infants
NCT03227029Phase 1Completed
- Sponsor
- National Institute of Allergy and Infectious Diseases
- Start
- Sep 2017
- Primary completion
- Dec 2019
- Modality
- Live Attenuated Vaccines
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of RSVt vaccine and RSV MEDI ΔM2-2 in respiratory syncytial virus infection (RSV), sponsored by National Institute of Allergy and Infectious Diseases. Started Sep 2017; status: completed.
02
Drugs
RSVt vaccineRSV MEDI ΔM2-2
03
Conditions
respiratory syncytial virus infection (RSV)
Beyond the preview
Go deeper on NCT03227029.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03227029.